trial
as of 2026-07-01Olanzapine Given in Combination With Zonisamide SR to Prevent Weight Gain in Schizophrenic Subjects
NCTId NCT00734435
at a glance
Phase 2 · Terminated
Enrollment 26 (actual)
Sponsored by Orexigen Therapeutics, Inc
Primary completion 2008-12
Synthesized from structured facts only — each point cited above.
Design & status
Phase
Phase 2
Status
Terminated
Enrollment
26 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2008-09
Primary completion
2008-12
Eligibility
ALL · 18 Years · 55 Years
Interventions & indications
Sponsors
Orexigen Therapeutics, IncLead Sponsor
Investigators
9
Alan Breier, MDPrincipal Investigator
Mohammed Alam, MDPrincipal Investigator
Gerald Maguire, MDPrincipal Investigator
Zinoviy Benzar, MDPrincipal Investigator
Mohammed Bari, MDPrincipal Investigator
Tran Johnson, MDPrincipal Investigator
Eduard Gfeller, MDPrincipal Investigator
Andrew Cutler, MDPrincipal Investigator
Robert A Riesenberg, MDPrincipal Investigator
Sites
9 total
National City, United StatesOrange, United StatesSan Diego, United StatesBradenton, United StatesMaitland, United StatesAtlanta, United StatesOak Brook, United StatesIndianapolis, United StatesBrooklyn, United States
Linked catalysts
1
Facts & assertions
4 sourced
Enrollment
26
Phase
PHASE2
Primary Completion Date
2008-12
Status
TERMINATED
relationships
The graph out of here
drug
drug
lead_sponsor
company
indication
investigator